Exploiting epigenetic vulnerabilities for cancer therapeutics.
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The rationale for applying epigenetic drugs to treat cancer is twofold. First, epigenetic changes are reversible, and drugs...
| Autores principales: | , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
2014
|